{"member_organisations": "", "identification_number": "91269481588-28", "fields_of_interest": "General and Institutional Affairs, Economy, finance and the euro, Trade, Competition, Consumers, International co-operation and development, Customs, Employment and Social Affairs, Business and Industry, Environment, Taxation, Justice and Fundamental Rights, Single market, Regional Policy, Research and innovation, External Relations, Public Health, Digital economy and society, Borders and Security", "head_office_address": "Novartis International AG Forum 1", "full_time_equivalent_fte": "5,75", "person_with_legal_responsibility": "Narasimhan Vas", "industry_forums": "", "grants": "", "inter_groups": "", "eu_initiatives": "Antimicrobial resistance (AMR) \nATMP Regulation \nBig data \nBiosimilars & generics \nClinical Trials Regulation \nData Protection Regulation \nEU IP policy \nEU Relative Efficacy Assessment (EU REA) \nEU research policy  \nEU trade policy \nHealth Systems Performance Assessment \nHealth Technology Assessment & Market Access \nIndustrial policy \nInnovative Medicines Initiative (IMI)  \nIn-Vitro Diagnostic Regulation  \nMedical Devices Regulation  \nOutcomes-based healthcare systems \nOrphan Medicinal Products Regulation  \nPaediatric Regulation \nPatient access to innovation \nPatient safety \nPharmaceuticals in the environment \nSustainable Development Goals", "level_of_interest": "global", "organisation_name": "Novartis International AG", "belgium_office_post_code": "", "number_of_persons_involved": "14", "person_in_charge_of_eu_relations": "Max von Olenhusen", "section": "II - In-house lobbyists and trade/business/professional associations", "source": "", "subsection": "Companies & groups", "belgium_office_phone": "(+32)2 246 1975", "overall_budget_turnover_as_a_range": "", "belgium_office_address": "Rue du Tr\u00f4ne 108", "no_geo_reference": true, "persons_accredited_for_access_to_european_parliament_premises": "CATTANEO#Ivana, Chauvet#Julie, DIEZ LORENTE#Gemma, G\u00d6TZ VON OLENHUSEN#Maximilian Alexander, JENEWEIN#Joerg, Moccaldi#Ludovica", "registration_date": "27/04/2009", "estimate_of_costs_absolute_amount": "", "website_address": "http://www.novartis.com", "commission_expert_groups_and_other_similar_entities_european_commission": "NA", "head_office_post_box": "", "head_office_city": "Basel", "membership": "Among others, Novartis is a member of the following associations: BusinessEurope, British Chamber of Commerce, EFPIA, EuropaBio, Medicines for Europe, MedTech Europe", "head_office_post_code": "CH-4002", "position": "Head of Brussels Office & EU Relations", "financial_year_start_date": "01/01/2017", "head_office_country": "Switzerland", "number_of_ep_accredited_persons": "6", "relevant_communication": "In November 2017, Novartis organized a panel debate in the European Parliament to raise awareness on breast cancer. The debate aimed at discussing ways to improve disease management and patient care. The event included representatives of the European Parliament, patient groups, medical societies, caregivers, Novartis and other companies. In addition to the event, there was an exhibition with patient testimonies at a premise outside of the Parliament.", "financial_year_end_date": "01/12/2017", "estimate_of_costs_as_a_range": "2250000-2499999", "overall_budget_turnover_absolute_amount": "0", "legal_status": "Corporation", "procurement": "", "customers": "", "belgium_office_post_box": "", "goals__remit": "Our vision is to be a trusted leader in changing the practice of medicine. Our mission is to discover new ways to improve and extend people's lives. We use science-based innovation to address some of society's most challenging healthcare issues. We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible. We also aim to provide a shareholder return that rewards those who invest their money, time and ideas in our company.", "belgium_office_city": "Brussels", "head_office_phone": "(+41)61 324 11 11"}